NovoCure Regulatory Approval
NovoCure received approval from Japan's Ministry of Health, Labour and Welfare for its Optune Pax device to treat adult patients with unresectable locally advanced pancreatic cancer. The approval was based on Phase 3 PANOVA-3 trial results showing statistically significant improvement in median overall survival. This marks a major commercial milestone for the company in Japan, where pancreatic cancer is the fourth leading cause of cancer death.
- Counterparty
- Ministry of Health, Labour and Welfare (MHLW)